Q2 2025 Gland Pharma Ltd Earnings Call Transcript
Key Points
- Gland Pharma Ltd (NSE:GLAND) reported a 5% increase in base business revenue, demonstrating resilience in a competitive environment.
- The company maintained a steady base business EBITDA margin of 34%, similar to the previous year.
- Gland Pharma Ltd (NSE:GLAND) successfully launched six new molecules across key markets, including four in the US, contributing to growth.
- The company entered into a strategic biologics CDMO collaboration with Dr. Reddy's Laboratories, leveraging its state-of-the-art manufacturing facility.
- Gland Pharma Ltd (NSE:GLAND) has a strong cash position with INR28,201 million in cash and cash equivalents, indicating financial stability.
- Cenexi, the European CDMO business, reported a negative EBITDA of INR685 million due to an extended shutdown and operational challenges.
- The company's consolidated EBITDA margin decreased to 21%, primarily impacted by losses at Cenexi.
- Gland Pharma Ltd (NSE:GLAND) experienced a slight delay in order pickup from Saudi Arabia, affecting revenue from the rest of the world markets.
- The gross margin for Q2 FY25 was 59%, down from 62% in the same period last year, mainly due to lower margins at Cenexi.
- Net profit for Q2 FY25 decreased by 16% compared to the same period last year, reflecting challenges in achieving profitability.
Good day, and welcome to Q2 FY25 earnings conference call of Gland Pharma Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Ankit Gupta. Thank you, and over to you, sir.
Thank you, Sagar. Good evening, everyone. We welcome you to Gland Pharma Earnings Conference Call for Q2 of FY25. My name is Ankit, and I head Investments, M&A and Corporate Strategy at Gland. In India office today, we have Mr. Srinivas Sadu, our Executive Chairperson and CEO; Mr. Ravi Mitra, our CFO. We also have Mr. Alain, the CEO of Cenexi, who is connected virtually from France. We'll begin the call with business highlights from Mr. Sadu, followed by an overview of Cenexi from Mr. Alain and lastly, the group financial overview by Mr. Ravi.
Before we proceed, I'd like to remind everyone that some of the statements made today will be forward-looking and are based on management's current estimates. These statements should be considered
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
